Skip to main content
Caplight Logo









Therabest

Therabest

Private
SeoulHealthcare & Life Scienceshttp://therabest.co.kr/

Last Round

Series C

Nov 19, 2021

Est. Valuation

$162.87M

Total Funding Raised

$22.05M

Company Overview

Therabest is a biotechnology company that develops next-generation immunotherapies using induced pluripotent stem cell (iPSC)-derived immune cells and nano-convergent drug delivery platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

natural killer cell therapyNK cell therapyinduced pluripotent stem cellsiPSCallogeneic cell therapyoff-the-shelf cell therapysolid tumor treatmentautoimmune cell therapycell therapy manufacturingbiotechnology R&Dclinical-stage biotechdrug licensingnext-gen immunotherapyoff-the-shelf medicinecell therapy platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Therabest Comparables

Compare Therabest with similar companies based on industry and business-model similarity.

Therabest comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HebeCell
89%
Shoreline Biosciences
84%
Neukio Biotherapeutics
84%

Therabest Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 19, 2021
Series BJun 21, 2021

Key People

Founding team and executive leadership

Youngbae Shin

CFO

Executive Team

Therabest Investors

Notable investors and investment history

Therabest investors
InvestorRounds
DA Value InvestmentSeries C
Meritz Securities Co., Ltd.Series C
DS Asset ManagementSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 2, 2026

    Monthly visitors increased 51% MoM to 4.5K.

  • Jan 20, 2026

    Monthly visitors increased 171% MoM, reaching 3.8K.

Therabest Filings

Explore SEC and related filing metadata, where available.

Therabest filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Therabest's valuation, stock price, and market status.

Is Therabest a public or private company?

Therabest is a private company.

What is the current stock price of Therabest?

Therabest is a private company with no public stock price. No recent secondary market data is available.

How much is Therabest worth (valuation)?

Therabest's valuation is estimated at $162.9M based on funding round data.

Can I buy Therabest stock?

Therabest shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Therabest's last funding round?

Therabest's most recent funding round was Series C on November 19, 2021.

Who are the main investors in Therabest?

Key investors in Therabest include DA Value Investment, Meritz Securities Co., Ltd., DS Asset Management.

Will Therabest IPO soon?

No public IPO plans have been announced for Therabest.

How can I track Therabest secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Therabest's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range13
Year Founded2012
Last FundingNov 19, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?